PH12012501293A1 - Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same - Google Patents

Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Info

Publication number
PH12012501293A1
PH12012501293A1 PH1/2012/501293A PH12012501293A PH12012501293A1 PH 12012501293 A1 PH12012501293 A1 PH 12012501293A1 PH 12012501293 A PH12012501293 A PH 12012501293A PH 12012501293 A1 PH12012501293 A1 PH 12012501293A1
Authority
PH
Philippines
Prior art keywords
pyrrolidine
dione
quinolin
pyrrolo
indol
Prior art date
Application number
PH1/2012/501293A
Other languages
English (en)
Inventor
Neil R Barnes
Jian-Xie Chen
John C Kane
Christopher A Lee
Martin P Redmon
David P Reed
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of PH12012501293A1 publication Critical patent/PH12012501293A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH1/2012/501293A 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same PH12012501293A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (1)

Publication Number Publication Date
PH12012501293A1 true PH12012501293A1 (en) 2013-01-07

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2012/501293A PH12012501293A1 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
PH12014500310A PH12014500310A1 (en) 2009-12-23 2014-02-06 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12014500310A PH12014500310A1 (en) 2009-12-23 2014-02-06 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN104910159A (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TWI506026B (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4171061B2 (ja) * 2005-02-09 2008-10-22 アーキュール,インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2014000253A (es) 2011-07-07 2014-10-17 Arqule Inc Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
TW201350483A (zh) * 2012-04-23 2013-12-16 Arqule Inc 高純度吡咯並喹啉基-吡咯-2,5-二酮及吡咯並喹啉基-吡咯啶-2,5-二酮以及彼等之製備方法
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
AU2072201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
IL161436A0 (en) * 2002-07-31 2004-09-27 Firmenich & Cie A process for the optical resolution of a precursor of sclareolide
CA2573508A1 (en) * 2004-09-10 2006-03-23 Wyeth Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives
JP4171061B2 (ja) * 2005-02-09 2008-10-22 アーキュール,インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−2,5−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
EP2173748B1 (en) * 2007-06-22 2011-08-31 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
TW201350483A (zh) * 2012-04-23 2013-12-16 Arqule Inc 高純度吡咯並喹啉基-吡咯-2,5-二酮及吡咯並喹啉基-吡咯啶-2,5-二酮以及彼等之製備方法

Also Published As

Publication number Publication date
CN104910159A (zh) 2015-09-16
WO2011079142A3 (en) 2011-11-24
MX2012007259A (es) 2015-05-15
CN102834097A (zh) 2012-12-19
AU2010336533A1 (en) 2012-07-12
US8552192B2 (en) 2013-10-08
AU2015243015A1 (en) 2015-11-05
CA2785503A1 (en) 2011-06-30
JP2013515737A (ja) 2013-05-09
PH12014500310A1 (en) 2015-09-28
HK1215025A1 (zh) 2016-08-12
JP2016041712A (ja) 2016-03-31
CN102834097B (zh) 2015-06-17
AU2010336533B9 (en) 2015-10-08
KR20160121602A (ko) 2016-10-19
NZ600800A (en) 2014-10-31
NZ628087A (en) 2016-02-26
TWI506026B (zh) 2015-11-01
MY169232A (en) 2019-03-19
AU2015243015B2 (en) 2017-02-02
TWI557125B (zh) 2016-11-11
TW201542546A (zh) 2015-11-16
SG181927A1 (en) 2012-07-30
US20110160242A1 (en) 2011-06-30
EP3081567A3 (en) 2016-11-16
AU2010336533B2 (en) 2015-09-10
WO2011079142A2 (en) 2011-06-30
US8871933B2 (en) 2014-10-28
RU2012131344A (ru) 2014-01-27
KR101669707B1 (ko) 2016-10-27
BR112012015656A2 (pt) 2016-05-10
US20160024076A1 (en) 2016-01-28
KR20120113760A (ko) 2012-10-15
RU2556205C2 (ru) 2015-07-10
CO6561823A2 (es) 2012-11-15
EP2515904A4 (en) 2013-07-03
TW201643163A (zh) 2016-12-16
EP2515904A2 (en) 2012-10-31
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
EP3081567A2 (en) 2016-10-19
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
PH12012501293A1 (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2010093789A3 (en) A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lh-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
PH12013500154A1 (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MY140324A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
MY148385A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
GEP20135858B (en) Compound with serotoninergic activity, method of its preparation, and pharmaceutical composition containing thereof
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
TH136969A (th) องค์ประกอบไพร์โรโลควิโนลินิล-ไพร์โรลิดีน-2,5-ไดโอนบริสุทธิ์ และวิธีการสำหรับการจัดเตรียมและการใช้สารนั้น
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.
GR1007745B (el) Φαρμακευτικη συνθεση που εμπεριεχει φθοροκινολονη και γλυκοκορτικοειδες καθως και μεθοδος για την προετοιμασια της